Edition:
United States

Profile: AstraZeneca PLC (AZN)

AZN on New York Consolidated

31.13USD
22 Jul 2016
Change (% chg)

$0.60 (+1.97%)
Prev Close
$30.53
Open
$30.44
Day's High
$31.23
Day's Low
$30.40
Volume
12,323,120
Avg. Vol
4,738,041
52-wk High
$34.88
52-wk Low
$26.97

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Respiratory, Inflammation and Autoimmunity

The Company's RIA marketed products include Accolate (zafirlukast), which is an oral leukotriene receptor antagonist used for the treatment of asthma; Bricanyl Turbuhaler (terbutaline), which is a short-acting beta2-agonist used for the acute treatment of bronchial-obstructive symptoms in asthma and Chronic obstructive lung disease (COPD); Duaklir Genuair (aclidinium/formoterol in a dry powder inhaler) is a fixed dose combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic receptor agonist (LABA) for the maintenance treatment of COPD; Eklira Genuair/Tudorza/Bretaris (aclidinium, a LAMA), which is used as treatment for patients with symptomatic mild to moderate COPD; Oxis Turbuhaler (formoterol in a dry powder inhaler), which is an onset, long-acting beta2-agonist used for the treatment of bronchial-obstructive symptoms in asthma and COPD, and Pulmicort Turbuhaler/Pulmicort Flexhaler (budesonide), which is an inhaled corticosteroid used for maintenance treatment of asthma. It also offers Pulmicort Respules (budesonide inhalation suspension), which is a corticosteroid administered through a nebulizer for the treatment of asthma in both children and adults; Rhinocort (budesonide), which is a nasal steroid used as a treatment for allergic rhinitis (hay fever), perennial rhinitis and nasal polyps; Symbicort pMDI (budesonide/formoterol in a pressurized metered-dose inhaler), which is a combination of an inhaled corticosteroid and a fast onset, long-acting beta2-agonist used for maintenance treatment of asthma and COPD, including chronic bronchitis and emphysema in the United States, Australia and some other markets, and Symbicort Turbuhaler (budesonide/formoterol in a dry powder inhaler) is a combination of an inhaled corticosteroid and onset, long-acting beta2-agonist used for the maintenance treatment of asthma and COPD. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist that produces long-term benefit in asthma by addressing imbalances in the immune system.

Cardiovascular and Metabolic diseases

The Company's marketed products under cardiovascular area include Atacand/Atacand HCT/Atacand Plus (candesartan cilexetil), which is an angiotensin II antagonist used for the first line treatment of hypertension and symptomatic heart failure; Brilinta/Brilique (ticagrelor), which is an oral antiplatelet for acute coronary syndromes (ACS); Crestor (rosuvastatin calcium), which is a statin for dyslipidaemia and hypercholesterolemia, and Plendil (felodipine), which is a calcium antagonist for hypertension and angina. It also offers Seloken/Toprol-XL (metoprolol succinate), which is a beta-blocker once daily tablet for control of hypertension, heart failure and angina; Tenormin (atenolol), which is a cardio-selective beta-blocker for hypertension, angina pectoris and other cardiovascular (CV) disorders, and Zestril (lisinopril dihydrate), which is an angiotensin-converting enzyme inhibitor for a range of CV diseases, including hypertension.

The Company's marketed products under metabolic area include Byetta (exenatide injection), which is a twice-daily injectable glucagon-like peptide 1 (GLP-1) receptor agonist indicated to improve glycemic control in adults with Type 2 diabetes; Bydureon (exenatide extended-release for injectable suspension), which is a once-weekly GLP-1 receptor agonist available as a single-dose tray or a single-dose pen indicated to improve glycemic control, in adults with Type 2 diabetes; Farxiga/Forxiga (dapagliflozin), which is a selective inhibitor of human sodium-glucose co-transporter 2 (SGLT-2 inhibitor) to manage glycemic control in adult patients with Type 2 diabetes mellitus, and Kombiglyze XR (saxagliptin and metformin XR), which combines saxagliptin (Onglyza) and metformin extended release metformin (metformin XR) in a once daily tablet for Type 2 diabetes mellitus. It also offers Komboglyze (saxagliptin and metformin hydrochloride extended release), which combines saxagliptin (Onglyza) and extended release metformin (metformin XR) in a once-daily tablet for Type 2 diabetes; Komboglyze (saxagliptin and metformin hydrochloride), which combines saxagliptin (Onglyza) and metformin immediate release (metformin IR) in a twice-daily tablet for Type 2 diabetes; Onglyza (saxagliptin), which is an oral dipeptidyl peptidase 4 (DPP-4) inhibitor for Type 2 diabetes, and Symlin (pramlintide acetate), which is an injected amylin analogue for Type 1 and Type 2 diabetes in patients with inadequate glycemic control. Its products also include Xigduo (dapagliflozin and metformin hydrochloride), which combines dapagliflozin (Farxiga/Forxiga), an SGLT-2 inhibitor, and metformin IR, in a twice-daily tablet to improve glycemic control in adult patients with Type 2 diabetes who are inadequately controlled by metformin alone, and Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), which combines dapagliflozin (Farxiga/Forxiga), an SGLT2 inhibitor, and metformin XR, in a once-daily tablet to improve glycemic control in adult patients with Type 2 diabetes who are inadequately controlled by metformin alone.

Oncology

The Company markets a range of oncology products, including Arimidex (anastrozole),which is an aromatase inhibitor used to treat breast cancer; Casodex/Cosudex (bicalutamide), which is an anti-androgen therapy used to treat prostate cancer; Faslodex (fulvestrant), which is an injectable estrogen receptor antagonist used to treat hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following treatment with prior endocrine therapy, and Iressa (gefitinib), which is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that acts to block signals for cancer cell growth and survival advanced non-small cell lung cancer (NSCLC). Its products also include Nolvadex (tamoxifen citrate), which is used breast cancer treatment outside the United States; Lynparza (olaparib), which is an oral poly ADP-ribose polymerase (PARP) inhibitor approved in Europe for the treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer, and Zoladex (goserelin acetate implant), in one and three month subcutaneous or intra-muscular injections, which is a luteinizing hormone-releasing hormone (LHRH) agonist used to treat prostate cancer, breast cancer and certain benign gynecological disorders.

Infection, Neuroscience and Gastrointestinal

The Company markets a range of infection, neuroscience and gastrointestinal products, including Synagis (palivizumab), which is a humanised monoclonal antibody (MAb) used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients; Fluenz/FluMist (influenza vaccine live, intra-nasal), which is an intra-nasal, live, attenuated, trivalent influenza vaccine, and Merrem/Meronem (meropenem), which is a carbapenem anti-bacterial used to treat serious infections in hospitalized patients. It also offers Zinforo (ceftaroline fosamil), which is an injectable cephalosporin used in community-acquired pneumonia and complicated skin and soft tissue infections; Fluenz Tetra/FluMist Quadrivalent (influenza vaccine live, intra-nasal), which is an intra-nasal, live, attenuated, quadrivalent influenza vaccine; Naropin (ropivacaine), which is a long-acting local anesthetic for surgical anesthesia and acute pain management; Diprivan (propofol), which is an intravenous general anesthetic used to induce and maintain general anesthesia, intensive care sedation and conscious sedation for surgical and diagnostic procedures, and Naropin (ropivacaine), which is a long-acting local anesthetic for surgical anesthesia and acute pain management. Its products also include Seroquel XR (an extended release formulation of quetiapine fumarate), which is generally approved for the treatment of schizophrenia, bipolar disorder, major depressive disorder and, on a more limited basis, for generalized anxiety disorder; Xylocaine (lidocaine), which is a short-acting local anesthetic for topical and regional anesthesia; Zomig (zolmitriptan), which is used for the acute treatment of migraine, plus for the acute treatment of cluster headache in the European Union, and Vimovo (naproxen/esomeprazole magnesium), which is approved for symptomatic relief in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis in patients at risk of developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers. It markets products, including Losec/Prilosec (omeprazole), which is a proton pump inhibitor used to treat acid-related diseases, and Nexium (esomeprazole magnesium), which is a proton pump inhibitor used to treat acid-related diseases.

Company Address

AstraZeneca PLC

- Legal Department, 2 Kingdom St
LONDON     W2 6BD
P: +4420.73045000
F: +4420.76048151

Company Web Links